PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 095/3-001.

U.S. Patent and TrademAt Office U.S. DEPARTMENT OF COMMERCE
Control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/573.369 INFORMATION DISCLOSURE Filling Date March 26, 2006 STATEMENT BY APPLICANT First Named Inventor Philippe Dupraz (use as many sheets as necessary) **Art Unit Examiner Name** Sheet of 3 Attorney Docket Number ARS-126

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	U1	US-	•	,	•		
	U2	US-					
	U3	US-					
	U4	US-					
	U5	US-					
	U6	US-					
	U7	US-					
	U8	US-					
	U9	US-					

			PATENT DOCU	JMENTS		
Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (if known)	Publication Date Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	-
	F1	WO 99/53059 A1	10-21-1999	Genentech, Inc.,	All	<u> </u>
	F2	WO 00/47741 A1	08-17-2000	Amgen, Inc.	All	
	F3	WO 00/52158 A1	08-09-2000	Cell Genesys, Inc.	All	
	F4	EP 0 382 762 B1	12-15-1993	Edwards et al.	All	_
	F5				7,11	-
	F6					_
	F7					-

(Formula or	
Examiner	Date
Signature	
Signature	Considered
	- Touriside: Cd

"EXAMINET: Initial if reference considered, whether or not clistion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, incides copy of this form with next communication to applicant." Applicant's unique clastion designation number (optional). See Kind Codes of USPTO Americant in the Codes of USPTO

This collection of information is required by 37 CFR 197 and 1.9.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to proceed) an application. Conditionally is governed by 38 USF or 197 and USFTO to proceed an application. Conditionally is governed by 38 USFTO and USFTO and USFTO are supported an application. Conditionally is governed by 38 USFTO and USFTO are supported an application of the amount of the governed procedure and application of the amount of the governed procedure and procedure and application of the amount of the governed procedure and procedure and

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Receipt date: 12/26/2006

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449B/PTO **Application Number** 10/573,369 INFORMATION DISCLOSURE Filing Date March 26, 2006 STATEMENT BY APPLICANT First Named Inventor Philippe Dupraz **Group Art Unit** (use as many sheets as necessary) **Examiner Name** Sheet of Attorney Docket Number | ARS-126

NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue T2 Initials' No. number(s), publisher, city and/or country where published Database EMBL 'Online!, Database Accession No. BD599618, ASHKENAZI, A.J., et al. "Secretion of glycosylated protein with the use of tissue plasminogen activator prosequence" July 17, 2003, XP002267400. D1 Database GENESEQ 'Online!, Database Accession No. AAY95831, MARTIN, F.H. et al. "Native mouse IgG1 signal peptide" November 7, 2000, XP002267401, R2 Database GENESEQ 'Online!. Database Accession No. AAY96081, PATEL, S. et al. "Mouse IgH signal peptide", December 5, 2000, XP002266931. ETCHEVERRY, T. et al. "Thirteen Amino Acid Propeptide from Tissue Plasminogen Activator Improves Expression of Recombinant TNFr-IgG1", April 25-29, 1999, ESACT R4 meeting, abstract, 01.07/P1.02. KÖHNE, C. et al. "Secretion of Glycosylation Site Mutants Can be Rescued by the Signal/Pro Sequence of Tissue Plasminogen Activator", Journal of Cellular Biochemistry, 1999, pp. 446-461, Vol. 75. R5 NAKAYAMA, K. "Furin: A Mammalian Subtilisin/Kex2p-Like Endoprotease Involved in Processing of a Wide Variety of Precursor Proteins", Biochem. J., 1997, pp. 625-635, Vol. R5 PFEFFER, S. R. et al. "Biosynthetic Protein Transport and Sorting by the Endoplasmic Reticulum and Golgi", Ann. Rev. Biochem., 1987, pp. 829-852, Vol. 56. R7 SEIDAH, N. G. et al. "Proprotein and Prohormone Convertases: a Family of Subtilases Generating Diverse Bioactive Polypeptides", Brain Research, 1999, pp. 45-62, Vol. 848. R8 SHOTWELL, M. A. et al. "Regulation of Amino Acid Transport System L in Chinese Hamster Ovary Cells", The Journal of Biological Chemistry, March 25, 1982, pp. 2974-2980, Vol. 257, No. 6. Rq THOMAS, G. "Furin at the Cutting Edge: From Protein Traffic to Embryogenesis and Disease", Nature Reviews Molecular Cell Biology, October 2002, pp. 753-766, Vol. 3. R10 WATANABE, T. et al. "Sequence Requirements for Precursor Cleavage within the Constitutive Secretory Pathway", The Journal of Biological Chemistry, April 25, 1992, pp. 8270-8274, Vol. 267, No. 12.

Examiner		Date	
Signature		Considered	
*EXAMINER: Initial	reference considered, whether or not citation is in conformance with MPEP		
and not considered. In-	had come of this form with and a second to all comornaide will wire	ous. Draw line th	rough citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

and not considered, include copy of this form with next communication to applicant.

Applicants runger clatified next particular number (optional). "Applicants to place a check mark here if English language Translation is attached.

The consideration of information is required by 3° CPR 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) as application. Confiderationally is governed by 3° U.S.C. 122 and 3° CPR 114. This collection is estimated to take 2 hours to complete, including the control of th gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandra, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Receipt date: 12/26/2006

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute	for form 1449B/P	ΤΟ.		Cor	Complete if Known		
	RMATION		OSLIDE	Application Number	10/573,369		
	EMENT B			Filing Date	March 26, 2006		
SIAI	CINICIAI B	TAP	LICANI	First Named Inventor	Philippe Dupraz		
(use as many sheets as necessary)				Group Art Unit			
				Examiner Name			
Sheet	3	of	3	Attorney Docket Number ARS-126			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city ardior country where published.	T ²
	R12	LOH, D. Y. et al. "Molecular Basis of a Mouse Strain-Specific Anti-Hapten Response", Cell, May 1983, pp. 85-93, Vol. 33.	
	R13	SwissProt Accession No. P00750, "Tissue-Type Plasminogen Activator", July 1986, pp. 1-10.	
	R14	EMBL Accession No. M13331, WEAVER, D. et al. "Altered repertoire of endogenous immunoglobulin gene expression in transgenic mice containing a rearranged mu heavy chain gene", April 27, 1993.	
	R15		
	R16		
	R17		
	R18		
	R19		
	R20		
	R21		
	R22		
	R23		Ħ

Examiner	/Maria Marvich/		Date	00/40/0000
Signature	/ivialia ivial vicii/		Considered	09/18/2009
*EXAMINER: Initial	f reference considered, whether or not citation is	in conformance with MPEP 60		ough citation if not in conformance
and not considered. In	clude copy of this form with next communication to ap	plicant.	o. Dide inc th	ough diation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

"Applicant's unjugic ultition designation number (optional)." Applicant is unjugic ultimor designation in attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to fit (and by the USFTO to process) an application. Confidentially is governed by 35 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to lake 2 Davis to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time by or require to complete this form and/or suggestions for reducing this burden, should be sent to the other information CVI. S. Patient and Tackersark Office, P.O. Box 1450, Alexandra, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2